Latest Breaking News On - Bioscience inc - Page 6 : comparemela.com

Think Bioscience raises $26M to find 'pockets' for drug therapies – Boulder Daily Camera

Think Bioscience raises $26M to find 'pockets' for drug therapies – Boulder Daily Camera
dailycamera.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailycamera.com Daily Mail and Mail on Sunday newspapers.

Jerome foxBioscience incThink bioscience

Think Bioscience raises $26M to find 'pockets' for drug therapies – BizWest

Think Bioscience raises $26M to find 'pockets' for drug therapies – BizWest
bizwest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizwest.com Daily Mail and Mail on Sunday newspapers.

United statesJerome foxBioscience incThink bioscience

North American Morning Briefing: Stock Futures -2-

North American Morning Briefing: Stock Futures -2-
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

United statesShamal sinaUnited kingdomPerth and kinrossJapan generalAptose bioscncesLori oneillWilliam blairLaurie smaldone alsupPiper sandlerRaymond jamesGeorge westonBenjamin netanyahuCreative media community trust corpInfo servicesAvient corp

PURE Bioscience Appoints Darin Zehr to Board of Directors

PURE Bioscience, Inc. , creator of the patented non-toxic silver dihydrogen citrate antimicrobial, today reported the appointment of Darin Zehr to its Board of Directors, effective as of May 1,.

United statesNew yorkBeaver campSan diego countyLewis countyRobert bartlettEl cajonDarin zehrIntralox companyFood sanitationBioscience incAudit committeeUniversity of new yorkKraft foodsYork state cheese manufacturer associationCompensation committee

Daré Bioscience (NASDAQ:DARE) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Daré Bioscience (NASDAQ:DARE – Free Report) in a report published on Wednesday morning, Benzinga reports. They currently have a $6.00 price objective on the biotechnology company’s stock. A number of other research analysts also recently issued reports on the stock. Dawson James downgraded shares of Daré […]

United statesDawson jamesBioscience company profileBioscience incExchange commissionArmistice capitalFree reportCapital managementBioscience priceGet free reportFunds weigh in on darBioscience companyBioscience dailyDaré bioscienceNasdaq dareReiterated rating